CCS
LABU icon

Crosspoint Capital Strategies’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Crosspoint Capital Strategies’s Portfolio LABU Stock Details LABU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-25
Closed -$8K – 17
2022
Q1 		$8K Buy
+25
New +$9.43K 0.02% 32
2017
Q1 		– Sell
-42
Closed -$26K – 115
2016
Q4 		$26K Buy
+42
New +$31.5K 0.02% 59
2016
Q2 		– Sell
-150
Closed -$82K – 146
2016
Q1 		$82K Buy
+150
New +$94.9K 0.08% 48

Other funds holding LABU

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AIP
Ahrens Investment Partners Lafayette, Louisiana $202M AUM 3.91% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
Requisite Capital Management Dallas, Texas $537M AUM 12.29% 1-Year Est. Return

Crosspoint Capital Strategies's LABU Position: Q2 2022 in Review

Crosspoint Capital Strategies sold out of Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q2 2022, closing a stake of 25 shares — an estimated $8K sold.

Crosspoint Capital Strategies first reported a position in LABU in Q1 2016 and held it in 3 quarters. The position peaked at $82K in Q1 2016. 47 funds tracked by Wall St. Rank hold LABU as of Q2 2022.

  • Crosspoint Capital Strategies reported no remaining Direxion Daily S&P Biotech Bull 3X ETF position as of Q2 2022 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 25 Direxion Daily S&P Biotech Bull 3X ETF shares in Q2 2022, an estimated $8K.
  • Crosspoint Capital Strategies first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q1 2016 and held it in 3 quarters.
  • Crosspoint Capital Strategies's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $82K in Q1 2016.
  • 47 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q2 2022.

Based on Crosspoint Capital Strategies's 13F filing for Q2 2022, filed 12 Aug 2022.